Get access to our best features
Get access to our best features
Published 26 days ago

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Summary by Helena Independent Record
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1Patients with HER2-low status may now be eligible for HER2-targeted treatment, which could significantly improve their outcome.2The VENTANA HER2 (4B5) test is the only approved companion…

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 69% of the sources are Center
69% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)